Noxopharm Limited
NOXOF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | $20 | $13 | $127 | $190 |
| - Cash | $2 | $3 | $14 | $27 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $17 | $10 | $113 | $163 |
| Revenue | $2 | $6 | $5 | $6 |
| % Growth | -60.1% | 10.7% | -3.2% | – |
| Gross Profit | -$1 | $6 | $5 | $5 |
| % Margin | -22.3% | 97.4% | 95.2% | 95.3% |
| EBITDA | -$5 | -$15 | -$15 | -$14 |
| % Margin | -191.6% | -246.3% | -275.3% | -255.8% |
| Net Income | -$4 | -$15 | -$19 | -$9 |
| % Margin | -149.1% | -250.5% | -343.9% | -166.7% |
| EPS Diluted | -0.012 | -0.052 | -0.064 | -0.035 |
| % Growth | 76.3% | 19.7% | -81.1% | – |
| Operating Cash Flow | -$1 | -$11 | -$14 | -$9 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1 | -$11 | -$14 | -$9 |